EDAP TMS S.A. (FOCL)

Market Cap	193.00M +120.8%
Revenue (ttm)	79.31M +60.7%
Net Income	-38.97M
EPS	-1.04
Shares Out	45.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,913
Open	4.280
Previous Close	4.320
Day's Range	4.160 - 4.405
52-Week Range	1.750 - 6.400
Beta	-0.05
Analysts	Buy
Price Target	8.80 (+109.52%)
Est. Earnings	Nov 5, 2026

About FOCL

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment re...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1979
• Employees: 289
• Stock Exchange: Nasdaq
• Ticker Symbol: FOCL
• Website: https://investor.focalone.com

Financial Performance

In 2025, EDAP TMS's revenue was $70.53 million, an increase of 1.63% compared to the previous year's $69.40 million. Losses were -$29.25 million, 42.1% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for FOCL stock is "Buy." The 12-month stock price target is $8.8, which is an increase of 109.52% from the latest price.

Price Target

$8.8

(109.52% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 3, 2026

Data Sources Report a data error